Ramucirumab for the treatment of gastroesophageal cancers

INTRODUCTION: In 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab for use in the second line setting of advanced or metastatic, gastric or gastroesophageal adenocarcinoma (GEAC) based on the result of Phase III clinical trials; REGARD and RAINBOW. AREAS COVERED: We briefly revi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Expert Opin Orphan Drugs
Auteurs principaux: Shimodaira, Y., Elimova, E., Wadhwa, R., Shiozaki, H., Charalampakis, N., Planjery, V., Rogers, J.E., Song, S., Ajani, J.A.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5001688/
https://ncbi.nlm.nih.gov/pubmed/27570714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/21678707.2015.1040390
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires